NLS Pharmaceutics Analyst Ratings
NLS Pharmaceutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 09/06/2022 | 933.24% | Laidlaw & Co. | → $6 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1966.47% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 03/03/2021 | 1277.65% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 8 月 11 日 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 09/06/2022 | 933.24% | Laidlaw & Co. | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 12 月 3 日 | 1966.47% | 布鲁克林资本 | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 03/03/2021 | 1277.65% | Maxim 集团 | → 8 美元 | 启动覆盖范围开启 | → 购买 |
NLS Pharmaceutics Questions & Answers
NLS 药学问题与解答
The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on November 8, 2022. The analyst firm set a price target for $0.00 expecting NLSP to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
Maxim集团于2022年11月8日公布了NLS制药公司（纳斯达克股票代码：NLSP）的最新目标股价。该分析公司将目标股价定为0.00美元，预计NLSP将在12个月内降至12个月内（可能下跌-100.00％）。去年有2家分析公司公布了评级。
The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics downgraded their hold rating.
NLS Pharmacetics（纳斯达克股票代码：NLSP）的最新分析师评级由Maxim集团提供，NLS Pharmacetics下调了持仓评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on November 8, 2022 so you should expect the next rating to be made available sometime around November 8, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与NLS Pharmacetics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。NLS Pharmacetics的最新评级是在2022年11月8日公布的，因此您应该预计下一个评级将在2023年11月8日左右公布。
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.58, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的NLS Pharmacetics（NLSP）评级已下调，目标股价为0.00美元至0.00美元。NLS Pharmacetics（NLSP）目前的交易价格为0.58美元，超出了分析师的预期区间。